182 related articles for article (PubMed ID: 34073780)
1. Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment.
Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Fahmy UA; Badr-Eldin SM
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34073780
[TBL] [Abstract][Full Text] [Related]
2. Optimized semisolid self-nanoemulsifying system based on glyceryl behenate: A potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells.
Badr-Eldin SM; Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Okbazghi SZ; Fahmy UA
Int J Pharm; 2021 May; 600():120493. PubMed ID: 33744452
[TBL] [Abstract][Full Text] [Related]
3. RETRACTED: Aldawsari et al. Lipidic Nano-Sized Emulsomes Potentiates the Cytotoxic and Apoptotic Effects of Raloxifene Hydrochloride in MCF-7 Human Breast Cancer Cells: Factorial Analysis and In Vitro Anti-Tumor Activity Assessment.
Aldawsari HM; Ahmed OAA; Alhakamy NA; Neamatallah T; Fahmy UA; Badr-Eldin SM
Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399356
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
Kanade R; Boche M; Pokharkar V
AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706
[TBL] [Abstract][Full Text] [Related]
6. The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells.
Awan ZA; Fahmy UA; Badr-Eldin SM; Ibrahim TS; Asfour HZ; Al-Rabia MW; Alfarsi A; Alhakamy NA; Abdulaal WH; Al Sadoun H; Helmi N; Noor AO; Caraci F; Almasri DM; Caruso G
Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32604984
[TBL] [Abstract][Full Text] [Related]
7. Potentiality of raloxifene loaded melittin functionalized lipidic nanovesicles against pancreatic cancer cells.
Fahmy UA; Badr-Eldin SM; Aldawsari HM; Alhakamy NA; Ahmed OAA; Radwan MF; Eid BG; Sayed SRM; El Sherbiny GA; Abualsunun W
Drug Deliv; 2022 Dec; 29(1):1863-1877. PubMed ID: 35708464
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin-Loaded Emulsomes Exhibit Improved Cytotoxic and Apoptosis in Prostate Cancer Cells.
Alhakamy NA; Badr-Eldin SM; Aldawsari HM; Alfarsi A; Neamatallah T; Okbazghi SZ; Fahmy UA; Ahmad OAA; Eid BG; Mahdi WA; Alghaith AF; Alshehri S; Md S
AAPS PharmSciTech; 2021 Jun; 22(5):177. PubMed ID: 34128106
[TBL] [Abstract][Full Text] [Related]
9. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
10. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
Murthy A; Ravi PR; Kathuria H; Malekar S
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study.
Shah NV; Seth AK; Balaraman R; Aundhia CJ; Maheshwari RA; Parmar GR
J Adv Res; 2016 May; 7(3):423-34. PubMed ID: 27222747
[TBL] [Abstract][Full Text] [Related]
12. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
[TBL] [Abstract][Full Text] [Related]
13. Formulation and Characterization of Raloxifene Nanostructured Lipid Carriers for Permeability and Uptake Enhancement Applications.
Sharma A; Streets J; Bhatt P; Patel P; Sutariya V; Varghese Gupta S
Assay Drug Dev Technol; 2022; 20(4):164-174. PubMed ID: 35617693
[TBL] [Abstract][Full Text] [Related]
14. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Du X; Gao N; Song X
Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
[TBL] [Abstract][Full Text] [Related]
15. The Encapsulation of Febuxostat into Emulsomes Strongly Enhances the Cytotoxic Potential of the Drug on HCT 116 Colon Cancer Cells.
Fahmy UA; Aldawsari HM; Badr-Eldin SM; Ahmed OAA; Alhakamy NA; Alsulimani HH; Caraci F; Caruso G
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33050567
[TBL] [Abstract][Full Text] [Related]
16. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
[TBL] [Abstract][Full Text] [Related]
17. Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation.
Sinai Kunde S; Wairkar S
Int J Pharm; 2022 Jul; 623():121926. PubMed ID: 35716974
[TBL] [Abstract][Full Text] [Related]
18. Optimized Apamin-Mediated Nano-Lipidic Carrier Potentially Enhances the Cytotoxicity of Ellagic Acid against Human Breast Cancer Cells.
Badr-Eldin SM; Aldawsari HM; Fahmy UA; Ahmed OAA; Alhakamy NA; Al-Hejaili OD; Alhassan AA; Ammari GA; Alhazmi SI; Alawadi RM; Bakhaidar R; Alamoudi AJ; Neamatallah T; Tima S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012704
[TBL] [Abstract][Full Text] [Related]
19. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies.
Alhalmi A; Amin S; Khan Z; Beg S; Al Kamaly O; Saleh A; Kohli K
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
